CD19 and lymphoma: In a post hoc analysis of 12 patients with R/R aggressive B‐NHL in the TRANSCEND study who had received anti‐CD19 therapy prior to liso‐cel therapy (where subsequent biopsy showed CD19‐positive lymphoma), the ORR was 92% (11 patients); 6 patients (50%) achieved a CR and 5 (42%) achieved a PR; 5 patients had a DOR ≥9 months122